| Perrigo (PRGO) Reliance on International Sales: What Investors Need to Know |
Evaluate Perrigo's (PRGO) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. |
zacks.com |
2025-05-13 14:23:20 |
Czytaj oryginał (ang.) |
| Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y |
PRGO reports mixed first-quarter 2025 results. The top line declines, largely due to the loss of sales stemming from exited businesses and product lines. |
zacks.com |
2025-05-07 18:25:34 |
Czytaj oryginał (ang.) |
| Perrigo Company plc (PRGO) Q1 2025 Earnings Call Transcript |
Perrigo Company plc (NYSE:PRGO ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations Patrick Lockwood-Taylor - President & Chief Executive Officer Eduardo Bezerra - Chief Financial Officer Conference Call Participants Susan Anderson - Canaccord Genuity Keith Devas - Jefferies Daniel Biolsi - Hedgeye Operator Good morning, ladies and gentlemen and welcome to the Perrigo Q1 2025 Financial Results Conference Call. At this time, all lines are in listen-only mode. |
seekingalpha.com |
2025-05-07 18:14:18 |
Czytaj oryginał (ang.) |
| Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-07 14:36:31 |
Czytaj oryginał (ang.) |
| Perrigo (PRGO) Q1 Earnings Beat Estimates |
Perrigo (PRGO) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.29 per share a year ago. |
zacks.com |
2025-05-07 12:45:38 |
Czytaj oryginał (ang.) |
| Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations |
Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN , May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested businesses, exited product lines and currency translation. |
prnewswire.com |
2025-05-07 10:30:00 |
Czytaj oryginał (ang.) |
| Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock? |
PRGO's first-quarter top line is likely to have been impacted by exited businesses and product lines, and unfavorable currency movements. |
zacks.com |
2025-05-05 14:55:34 |
Czytaj oryginał (ang.) |
| Perrigo (PRGO) Earnings Expected to Grow: Should You Buy? |
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:06:11 |
Czytaj oryginał (ang.) |
| Perrigo Announces Quarterly Dividend |
DUBLIN , April 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. |
prnewswire.com |
2025-04-30 14:23:00 |
Czytaj oryginał (ang.) |
| Perrigo: Opill Shows Where The Company Wants To Be |
Perrigo's transformation from a low-margin generics manufacturer to a branded consumer self-care company hinges on the success of products like Opill and Mederma. Despite short-term revenue declines, Perrigo's margin expansion and cost-saving initiatives show promise for long-term growth and strategic focus. The company's financial health is under pressure, with high leverage and volatile infant formula business posing significant risks. |
seekingalpha.com |
2025-04-24 22:21:39 |
Czytaj oryginał (ang.) |
| Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025 |
DUBLIN , April 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025 financial results on Wednesday, May 7 th, 2025, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. |
prnewswire.com |
2025-04-23 20:47:00 |
Czytaj oryginał (ang.) |
| Trump Tariffs Could Have 'Significant Impact' On Perrigo Earnings, Says JP Morgan |
J.P. Morgan say s Perrigo Company plc's PRGO first-quarter 2025 earnings will be dominated by commentary on the potential impact of tariffs. The analyst says, “Tariffs could potentially have a significant impact on PRGO's near-term earnings. |
benzinga.com |
2025-04-21 18:38:34 |
Czytaj oryginał (ang.) |
| Investing in Perrigo (PRGO)? Don't Miss Assessing Its International Revenue Trends |
Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. |
zacks.com |
2025-03-05 12:15:29 |
Czytaj oryginał (ang.) |
| Perrigo Company plc (PRGO) 2025 Investor Day (Transcript) |
Perrigo Company plc (NYSE:PRGO ) Perrigo 2025 Investor Day February 28, 2025 8:00 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Patrick Lockwood-Taylor - President and Chief Executive Officer Eduardo Bezerra - Executive Vice President and Chief Financial Officer Triona Schmelter - President of CSCA Roberto Khoury - President of CSCI Ron Janish - Head of Global Supply Chain Abbie Lennox - Chief Scientific Officer David Ball - Chief Marketing & Digital Officer Charles Atkinson - General Counsel Conference Call Participants Keith Devas - Jefferies Susan Anderson - Canaccord Korinne Wolfmeyer - Piper Sandler Chris Schott - JPMorgan Daniel Biolsi - Hedgeye Operator Welcome to Perrigo's 2025 Investor Day. [Operator Instructions] Brad Joseph Good morning, good afternoon and good evening. |
seekingalpha.com |
2025-02-28 19:54:04 |
Czytaj oryginał (ang.) |
| Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y |
PRGO reports mixed Q4 2024 results. The decline in the company's top line is due to the loss of sales stemming from exited businesses and product lines. |
zacks.com |
2025-02-28 14:50:38 |
Czytaj oryginał (ang.) |
| Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day |
DUBLIN, Feb. 28, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that at its Virtual Investor Day, scheduled to begin today at 8:00 AM EST, the management team will lay out its plan to consumerize, simplify and scale its global self-care platform, with a clear path to return to stable and reliable performance. Perrigo's unique complementary businesses enables each individually to play a specific reinforcing role, where 1) store brands and infant formula generate cash for investments into the Company's key higher margin, higher growth or 'High-Grow' brands, 2) branding and innovation capabilities that deliver brand and store brand demand generation leading to stronger customer partnerships, 3) consumer-led innovation that is scaled across brands, store brands and geographies, and 4) the Company's global supply chain scale and reach with 100-plus molecules, at 100% consumer price point coverage, serves the most consumers. |
prnewswire.com |
2025-02-28 09:15:00 |
Czytaj oryginał (ang.) |
| Perrigo (PRGO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-27 22:31:09 |
Czytaj oryginał (ang.) |
| Perrigo (PRGO) Q4 Earnings Beat Estimates |
Perrigo (PRGO) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.86 per share a year ago. |
zacks.com |
2025-02-27 21:50:27 |
Czytaj oryginał (ang.) |
| Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations |
Making Significant Progress on Stabilizing, Streamlining and Strengthening Organization to Build Long-Term Sustainable, Value Accretive Growth Delivered Fiscal Year 2024 Adjusted EPS of $2.57 the Mid-Point of the Company's Communicated Guidance Range, on Reported Loss of $(1.17) Per Share Fourth Quarter 2024 Infant formula Net Sales Grew 17% Compared to the Prior Year Quarter, Due Primarily to Market Share Gains1 and Recovering Customer Inventory Levels DUBLIN , Feb. 27, 2025 /PRNewswire/ -- Fourth Quarter 2024 Highlights: Net sales of $1.14 billion declined 1.6%, as organic growth of 0.7% was more than offset by unfavorable impacts from divested businesses and exited product lines and currency translation of 2.3%. Organic2 net sales increased 0.7%, as higher net sales in the Nutrition, Skin Care and Women's Health Categories more than offset previously disclosed lost distribution of lower margin products in U.S. Store Brand of 1.2%, and lower net sales in the Pain and Sleep-Aids and Upper Respiratory categories stemming from a later start to the U.S. cough and cold season compared to the prior year. |
prnewswire.com |
2025-02-27 19:20:00 |
Czytaj oryginał (ang.) |
| Perrigo to Attend the UBS 2025 Global Consumer and Retail Conference |
DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS 2025 Global Consumer and Retail Conference, on Wednesday, March 12 at 10 AM ET in New York City. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. |
prnewswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Countdown to Perrigo (PRGO) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS |
Besides Wall Street's top -and-bottom-line estimates for Perrigo (PRGO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024. |
zacks.com |
2025-02-25 12:20:57 |
Czytaj oryginał (ang.) |
| Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect |
PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases. |
zacks.com |
2025-02-25 12:20:35 |
Czytaj oryginał (ang.) |
| What's in Store for These 5 Biotech Stocks This Earnings Season? |
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025. |
zacks.com |
2025-02-24 13:30:24 |
Czytaj oryginał (ang.) |
| Perrigo Increases Quarterly Dividend by 5% |
DUBLIN , Feb. 19, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors has approved a 5% increase in the Company's quarterly dividend to $0.290 per share, or $1.16 per share on an annual basis, up from $0.276 per share. This marks the 22nd consecutive year Perrigo has increased its dividend. |
prnewswire.com |
2025-02-19 17:11:00 |
Czytaj oryginał (ang.) |
| Opill® extends mission of breaking down birth control barriers with launch of multi-state college tour and expansion of partnerships |
--WNBA and Opill® continue partnership with Level The Court initiative-- GRAND RAPIDS, Mich. , Feb. 4, 2025 /PRNewswire/ -- Today, Opill®— the first and only daily birth control pill available without a prescription in the U.S. —launched an educational college campus tour and the next phase of its multiyear partnership with the Women's National Basketball Association (WNBA) with a goal of expanding reproductive health education and access to birth control resources. |
prnewswire.com |
2025-02-04 12:29:00 |
Czytaj oryginał (ang.) |
| Perrigo to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025, Host Virtual Investor Day on February 28, 2025 |
DUBLIN, Ireland , Jan. 31, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2024 financial results after the U.S. equity markets close on February 27, 2025. The Company plans to host its Virtual Investor Day on February 28, 2025, beginning at 8:00 AM EST. |
prnewswire.com |
2025-01-31 11:00:00 |
Czytaj oryginał (ang.) |
| Perrigo Paves The Way For Recovery With Margin Focus |
Perrigo is a focused OTC consumer healthcare player, slimming down operations and enhancing margins under new management, with a 4.6% dividend yield. Despite short-term pressures from a weak cold-and-flu season and infant formula production issues, PRGO is positioned for recovery and growth by 2026. The company is exploring new markets with a 'disruptive growth' team, focusing on women's health and GLP-1 side effect relief, aiming for mid-single-digit growth. |
seekingalpha.com |
2025-01-28 07:40:41 |
Czytaj oryginał (ang.) |
| Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer |
Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN , Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and scale. This expansion also further supports the Company's consumer-led innovation pipeline. |
prnewswire.com |
2025-01-06 10:00:00 |
Czytaj oryginał (ang.) |
| Perrigo (PRGO) Up 5.6% Since Last Earnings Report: Can It Continue? |
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-09 08:48:52 |
Czytaj oryginał (ang.) |
| Perrigo Company: Great Combination Of Future Growth With A Low Valuation |
Perrigo's long-term growth is driven by strategic initiatives like Project Energize, aiming for $140-$170 million in annualized savings by 2026. The company's reinvestments in leadership and IT, adding 200 years of consumer experience, are crucial for sustainable growth. Perrigo's supply chain reinvention program has already achieved $72 million in gross savings, enhancing cash flow and operational efficiency. |
seekingalpha.com |
2024-11-19 09:17:14 |
Czytaj oryginał (ang.) |
| Perrigo (PRGO) International Revenue Performance Explored |
Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. |
zacks.com |
2024-11-11 12:20:56 |
Czytaj oryginał (ang.) |
| Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated |
PRGO reports weaker-than-expected third-quarter 2024 results. Though management updates top-line guidance for 2024, it reaffirms the bottom-line outlook. |
zacks.com |
2024-11-06 15:01:10 |
Czytaj oryginał (ang.) |
| Perrigo Company plc (PRGO) Q3 2024 Earnings Call Transcript |
Perrigo Company plc (NYSE:PRGO ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations Patrick Lockwood-Taylor - President & Chief Executive Officer Eduardo Bezerra - Chief Financial Officer Conference Call Participants Susan Anderson - Canaccord Keith Devas - Jefferies Korinne Wolfmeyer - Piper Sandler Daniel Biolsi - Hedgeye Operator Good morning, ladies and gentlemen and welcome to the Perrigo Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode. |
seekingalpha.com |
2024-11-06 14:48:09 |
Czytaj oryginał (ang.) |
| Perrigo (PRGO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates |
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-06 12:35:42 |
Czytaj oryginał (ang.) |
| Perrigo (PRGO) Q3 Earnings and Revenues Lag Estimates |
Perrigo (PRGO) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.64 per share a year ago. |
zacks.com |
2024-11-06 10:40:18 |
Czytaj oryginał (ang.) |
| Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations |
Company Delivered Solid Third Quarter Financial Results, Including Meaningful Operating Income Growth and Margin Expansion Infant Formula Business Recovery Making Significant Progress, Including Perrigo Produced and Store Brand Infant Formula Market Share Gains1; Third Quarter 2024 Infant formula Net Sales Growth of +3% Compared to the Prior Year Quarter, +58% Sequentially Reaffirms Fiscal 2024 Adjusted EPS Outlook DUBLIN , Nov. 6, 2024 /PRNewswire/ -- Third Quarter 2024 Highlights: Net sales of $1.1 billion declined 3.2% versus the prior year quarter. Organic2 net sales decreased 2.4%, due primarily to -2.8 percentage points from previously disclosed lost distribution of lower margin products in U.S. Store Brand. |
prnewswire.com |
2024-11-06 08:30:00 |
Czytaj oryginał (ang.) |
| Perrigo to Report Q3 Earnings: Here's What to Expect |
PRGO's Q3 top line is expected to have been affected by lower net product sales in the United States and unfavorable currency movements in the quarter. |
zacks.com |
2024-11-04 10:25:17 |
Czytaj oryginał (ang.) |
| Perrigo Announces Quarterly Dividend |
DUBLIN , Nov. 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on December 17, 2024, to shareholders of record on November 29, 2024. About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. |
prnewswire.com |
2024-11-01 16:57:00 |
Czytaj oryginał (ang.) |
| Perrigo to Release Third Quarter 2024 Financial Results on November 6, 2024 |
DUBLIN , Oct. 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2024 financial results on Wednesday, November 6, 2024, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 96443. |
prnewswire.com |
2024-10-23 13:00:00 |
Czytaj oryginał (ang.) |
| WNBA Star Napheesa Collier Joins Team Opill® for Candid Conversations on Women's Health |
Opill® and Collier will hit the road to talk to women about their reproductive health options. GRAND RAPIDS, Mich. |
prnewswire.com |
2024-10-15 12:00:00 |
Czytaj oryginał (ang.) |
| Perrigo Announces Good Start® and Dr. Browns® Brand Partnership and Launch of Infant Formula Portfolio |
DUBLIN , Sept. 26, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced a new brand partnership: Good Start®1 and Dr. Brown's® 2 infant formula solutions. |
prnewswire.com |
2024-09-26 12:30:00 |
Czytaj oryginał (ang.) |
| PERRIGO ANNOUNCES THE CLOSING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY |
DUBLIN , Sept. 17, 2024 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) today announced the closing of a registered public offering by Perrigo Finance Unlimited Company, an indirect wholly-owned finance subsidiary of Perrigo (the "Issuer"), of $715 million aggregate principal amount of the Issuer's 6.125% Senior Notes due 2032 (the "USD Notes") and €350 million aggregate principal amount of the Issuer's 5.375% Senior Notes due 2032 (the "Euro Notes" and together with the USD Notes, the "Notes"). |
prnewswire.com |
2024-09-17 20:48:00 |
Czytaj oryginał (ang.) |
| PERRIGO ANNOUNCES THE PRICING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY |
DUBLIN , Sept. 12, 2024 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) today announced the pricing of a registered public offering by Perrigo Finance Unlimited Company, an indirect wholly-owned finance subsidiary of Perrigo (the "Issuer"), of $715 million aggregate principal amount of the Issuer's 6.125% Senior Notes due 2032 (the "USD Notes") and €350 million aggregate principal amount of the Issuer's 5.375% Senior Notes due 2032 (the "Euro Notes" and together with the USD Notes, the "Notes"). |
prnewswire.com |
2024-09-12 13:00:00 |
Czytaj oryginał (ang.) |
| Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary |
Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General Counsel DUBLIN , Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. |
prnewswire.com |
2024-09-04 12:00:00 |
Czytaj oryginał (ang.) |
| Perrigo to Attend the Piper Sandler Growth Frontiers Conference |
DUBLIN , Aug. 27, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Piper Sandler Growth Frontiers Conference on Tuesday, September 10 at 10:00 AM CDT. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. |
prnewswire.com |
2024-08-27 12:30:00 |
Czytaj oryginał (ang.) |
| Perrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer |
DUBLIN , Aug. 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer. In this newly created position, Dr. Ball will be responsible for an enterprise-wide marketing strategy that incorporates deep understanding of consumer needs and translates those into winning brand strategies, tactics, and actions. |
prnewswire.com |
2024-08-19 12:30:00 |
Czytaj oryginał (ang.) |
| Perrigo is voluntarily recalling 16,500 cans of baby formula because of high levels of Vitamin D |
Perrigo Co. Plc PRGO, +0.54% said Friday it's voluntarily recalling 16,500 cans of store brand Premium Infant Formula with iron milk-based powder because of levels of Vitamin D that exceed permitted levels. The Dublin-based provider of self-care and over-the-counter health and wellness products said the cans were shipped to H-E-B Grocery Company LP in Texas, and to CVS Health stores in Texas, Florida, California, South Carolina, Virginia, Indiana, Tennessee, New Jersey, Michigan, Pennsylvania, Rhode Island and Missouri. |
marketwatch.com |
2024-08-09 10:26:00 |
Czytaj oryginał (ang.) |
| Perrigo recalls 16,500 cans of its infant formula |
Perrigo has initiated a voluntary recall of three lots within one batch, or 16,500 cans, of its infant formula sold at H-E-B Grocery Company and CVS , a regulatory filing showed on Friday. |
reuters.com |
2024-08-09 10:21:40 |
Czytaj oryginał (ang.) |